Clinical Trials Logo

Filter by:
NCT ID: NCT05802563 Enrolling by invitation - Atrial Fibrillation Clinical Trials

Machine Learning Enabled Time Series Analysis in Medicine

ME-TIME
Start date: May 24, 2022
Phase:
Study type: Observational

The goal of this observational cohort study is to investigate the potential of fitness trackers in combination with machine learning algorithms to identify cardiovascular disease specific patterns. Two hundred participants will be enrolled: 1. 50 with heart failure 2. 50 with atrial fibrillation 3. 100 (healthy) individuals without the former two conditions All participants are given a Fitbit device and monitored for three months. Researchers will compare differences in heart rate variability patterns between the groups and devise a machine learning algorithm to detect these patterns automatically.

NCT ID: NCT05775354 Enrolling by invitation - Clinical trials for Coronary Artery Disease

Reviving Early Diagnosis of Cardiovascular Disease in the Utrecht Health Project

RED-LRGP
Start date: November 1, 2023
Phase: N/A
Study type: Interventional

The goal of this randomized trial is to compare the diagnostic yield of a screen-like early diagnosis strategy to usual primary care to detect coronary artery disease (CAD), atrial fibrillation (AF), heart failure (HF), and/or valvular heart disease (VHD) in community people aged 50-80 years who participate in the Utrecht Health Project. The diagnosis strategy consists of a questionnaire with questions related to symptoms suggestive of CAD, AF or HF, a focused physical examination, laboratory testing, electrocardiography, and echocardiography.

NCT ID: NCT05774756 Enrolling by invitation - Clinical trials for Hypothalamic Obesity

A Trial of Setmelanotide in Acquired Hypothalamic Obesity

Start date: April 26, 2023
Phase: Phase 3
Study type: Interventional

The goal of this trial is to learn how well Setmelanotide works to improve weight reduction, hunger, and quality of life in patients 4 years of age and older with acquired Hypothalamic Obesity (HO). To determine how well setmelanotide works and how safe it is, patients with HO will take a daily injection of either setmelanotide or placebo and complete trial assessments for up to 60 weeks.

NCT ID: NCT05772468 Enrolling by invitation - Pain Clinical Trials

Virtual Pain Care Trial

Start date: January 20, 2023
Phase: N/A
Study type: Interventional

The main objective of this study is to evaluate the effect on pain of Virtual Reality Therapy as add-on therapy during wound care procedures in adults.

NCT ID: NCT05750940 Enrolling by invitation - Iron-deficiency Clinical Trials

Oxidative Skeletal Muscle Metabolism in Chronic Heart Failure Patients With and Without Iron Deficiency

FERRIFY
Start date: October 5, 2021
Phase:
Study type: Observational [Patient Registry]

Observational study using in vivo noninvasive 31 phosphor magnetic resonance spectroscopy (31P MRS) to quantify the effect of iron deficiency (ID) on skeletal oxidative metabolism in patients with chronic heart failure (HF).

NCT ID: NCT05744024 Enrolling by invitation - Virtual Reality Clinical Trials

Non-pharmacological Pain Care During Complex Wound Care Procedures

Start date: November 17, 2022
Phase: N/A
Study type: Interventional

The main objective of this study is to evaluate the effect on pain and both Virtual Reality and Music Therapy as add-on therapy during wound care at the surgical wards in adults.

NCT ID: NCT05738798 Enrolling by invitation - Food Allergy Clinical Trials

Oral Immunotherapy in Young Children With Food Allergy

ORKA-NL
Start date: January 1, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to learn about oral immunotherapy in food allergic children < 30 months of age. The main question it aims to answer is: What is the clinical- and cost-effectiveness of early low-dose oral immunotherapy aimed at long-term tolerance induction. Participants will receive oral immunotherapy for 1 year with a maintenance dose of 300 mg allergenic protein and are compared with food allergic infants not receiving oral immunotherapy to compare with natural tolerance development.

NCT ID: NCT05710133 Enrolling by invitation - NSCLC Clinical Trials

The Food-effect on Alectinib Pharmacokinetics

Start date: February 1, 2024
Phase: N/A
Study type: Interventional

The goal of this food-effect study on Alectinib pharmacokinetics is to learn about the food effect of alectinib. The main question aims to answer is: • To determine the food-effect of a standardized Dutch breakfast on the pharmacokinetics of oral alectinib (Alecensa®), especially Peak Plasma Concentration (Cmax), Area under the plasma concentration versus time curve (AUC) and relative bioavailability, at steady state using a stable isotopically labelled microtracer approach. Participants will take alectinib-d6 (microtracer) with and without food on different days.

NCT ID: NCT05704322 Enrolling by invitation - Clinical trials for Spinal Cord Injuries

The Effectiveness of the Wim Hof Method in People With Spinal Cord Injury

Start date: March 27, 2023
Phase: N/A
Study type: Interventional

People with a spinal cord injury (SCI) often experience secondary medical complications. One of the methods that may help to prevent or deal with secondary complications in people with SCI is the Wim Hof Method (WHM). The WHM is based on three elements: 1) breathing exercises, 2) gradual cold exposure (cold showers, or cold water immersion), and 3) mindset. The primary objective of this randomized controlled trial is to assess the effects of WHM, involving breathing exercises, mindset (and cold exposure), on health-related quality of life in people with SCI. The secondary objectives are to assess the effects of WHM, involving breathing exercises, mindset (and cold exposure) in people with SCI on: inflammation markers, metabolic health, pulmonary function, body composition, sleep quality, spasticity, stress, and on chronic pain.

NCT ID: NCT05686330 Enrolling by invitation - Atrial Fibrillation Clinical Trials

Detection and Quantification of Atrial Fibrillation in High-risk Patients Using a Smartwatch Wearable (Apple Watch)

EQUAL
Start date: November 28, 2022
Phase: N/A
Study type: Interventional

This is a Randomized Controlled trial to evaluate if continuous heart rate and -rhythm monitoring with a photoplethysmography (PPG) smartwatch wearable (Apple Watch series 5) can detect atrial fibrillation at an early stage in cardiac patients with a known high risk of developing AF (ChadsVasc score ≥ 2 men; ≥3 women; age ≥ 65). In this monocenter, single arm, prospective randomized controlled trial the investigators will enroll 306 patients (153 per arm). An absolute in between-group difference of 8.5% in diagnosing patients with new AF in favor of the interventional group during a six month study period is hypothesized.